RESUMEN
OBJECTIVE: To show the impact of Sjögren's syndrome (SS) on maternal and fetal outcomes following pregnancy. METHODS: We performed a literature search based on PubMed, Web of science, Wan fang, China National Knowledge Infrastructure and ProQuest databases from 1 January 2007 to 6 November 2022. Grading of Recommendations, Assessment, Development, and Evaluations approach was used to assess the certainty of the evidence. Systematic reviews and meta-analyses were performed using RevMan 5.3 software. Pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using a random-effect, generic inverse variance method of DerSimonian and Laird. Trial sequential analyses were performed by TSA 0.9. RESULTS: Nine studies with 2341 patients and 2472 pregnancies with SS were included in our analysis. This current analysis showed pregnancy hypertension and preeclampsia/eclampsia to be significantly higher in pregnant women with SS compared to pregnant women without SS (OR: 1.65, 95% CI: 1.04-2.63; P = 0.03), (OR: 2.06, 95% CI: 1.16-3.65; P = 0.01) respectively. Cesarean section, thromboembolic disease, premature rupture of membranes, and spontaneous abortion were also significantly higher in the SS women with OR: 2.07, 95% CI: 1.48-2.88; P < 0.0001, OR: 9.45, 95% CI: 1.99-44.87; P = 0.005, OR: 1.36, 95% CI: 1.13-1.64; P = 0.001, OR: 9.30, 95% CI: 4.13-20.93; P < 0.00001, respectively. Significantly higher premature births were observed with infants who were born from SS mothers (OR: 2.19, 95% CI: 1.54-3.12; P < 0.0001). Infants defined as 'small for gestational age/intrauterine growth restriction' and 'weighing < 2500 g' were also significantly higher in patients suffering from SS (OR: 2.26, 95% CI: 1.38-3.70; P = 0.001), (OR: 3.84, 95% CI: 1.39-10.61; P = 0.009) respectively. In addition, live birth significantly favored infants who were born from mothers without SS (OR: 21.53, 95% CI: 8.36-55.44; P < 0.00001). Subgroup analysis by sample size revealed that pregnancy hypertension risk has significantly increased in small cohort (OR: 2.74, 95%CI: 1.45-5.18), and a slight increase was found in population-based studies (OR: 1.14, 95%CI: 0.91-1.43). In both small cohorts and population-based researches, cesarean section was significantly higher in SS (OR: 2.13, 95% CI: 1.29, 3.52; OR: 1.85, 95% CI: 1.29-2.64, respectively). The number of infants with intrauterine growth restriction did not grow in the population-based researches (OR: 2.07, 95%CI: 0.92-4.66) although there has been an increase in small reports (OR: 2.53, 95%CI: 1.16-5.51). Subgroup analysis was conducted on the basis of study location (not Asian vs. Asian countries) indicated that cesarean section was significantly higher in SS in both countries (OR: 1.69, 95% CI: 1.31-2.18; OR: 3.37, 95% CI: 2.39-4.77, respectively). CONCLUSION: This meta-analysis has shown SS to have a high impact on maternal and fetal outcomes following pregnancy.
Asunto(s)
Hipertensión , Preeclampsia , Nacimiento Prematuro , Síndrome de Sjögren , Lactante , Embarazo , Femenino , Humanos , Resultado del Embarazo/epidemiología , Retardo del Crecimiento Fetal/epidemiología , Retardo del Crecimiento Fetal/etiología , Cesárea , Síndrome de Sjögren/complicaciones , Síndrome de Sjögren/epidemiología , Nacimiento Prematuro/epidemiología , Nacimiento Prematuro/etiología , Preeclampsia/epidemiología , Preeclampsia/etiologíaRESUMEN
PURPOSE: The synergistic effects of combining arsenic compounds with imatinib against chronic myeloid leukemia (CML) have been established using in vitro data. We conducted a clinical trial to compare the efficacy of the arsenic realgar-indigo naturalis formula (RIF) plus imatinib with that of imatinib monotherapy in patients with newly diagnosed chronic phase CML (CP-CML). METHODS: In this multicenter, randomized, double-blind, phase 3 trial, 191 outpatients with newly diagnosed CP-CML were randomly assigned to receive oral RIF plus imatinib (n = 96) or placebo plus imatinib (n = 95). The primary end point was the major molecular response (MMR) at 6 months. Secondary end points include molecular response 4 (MR4), molecular response 4.5 (MR4.5), progression-free survival (PFS), overall survival (OS), and adverse events. RESULTS: The median follow-up duration was 51 months. Due to the COVID-19 pandemic, the recruitment to this study had to be terminated early, on May 28, 2020. The rates of MMR had no significant statistical difference between combination and imatinib arms at 6 months and any other time during the trial. MR4 rates were similar in both arms. However, the 12-month cumulative rates of MR4.5 in the combination and imatinib arms were 20.8% and 10.5%, respectively (p = 0.043). In core treatment since the 2-year analysis, the frequency of MR4.5 was 55.6% in the combination arm and 38.6% in the imatinib arm (p = 0.063). PFS and OS were similar at five years. The safety profiles were similar and serious adverse events were uncommon in both groups. CONCLUSION: The results of imatinib plus RIF as a first-line treatment of CP-CML compared with imatinib might be more effective for achieving a deeper molecular response (Chinadrugtrials number, CTR20170221).
Asunto(s)
Antineoplásicos , Arsénico , Leucemia Mielógena Crónica BCR-ABL Positiva , Humanos , Antineoplásicos/efectos adversos , Arsénico/uso terapéutico , Mesilato de Imatinib/efectos adversos , Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico , Pandemias , Resultado del TratamientoRESUMEN
BACKGROUND: Rheumatic diseases, mainly affecting women, including rheumatoid arthritis, Sjogren's syndrome, systemic lupus erythematosus, etc., are chronic, inflammatory, autoimmune disorders that may involve multiple organs or systems and are closely related to sexual health, which is an important aspect of human physical and mental health. Sjogren's syndrome (SS) is the second most common rheumatic illnesses after rheumatoid arthritis with a female predominance. At present, the research on sexual health of female SS patients is still scarce and difficult to summarize. OBJECTIVES: The objective of our study was to systematically review the literature for the influence of maternal SS on sexual health, such as sexual function, sex hormones, fertility, and pregnancy outcomes. METHODS: We performed a comprehensive literature search based on PubMed and Web of science databases from inception to 1 November 2022. Outcomes were divided into 4 categories: sex hormones, sexual function, fertility, and pregnancy and offspring outcomes. RESULTS: A total of 756 potentially eligible papers were retrieved. After eliminating duplicate articles and reviewing the titles and abstracts to exclude records, we read the remaining 92 articles in full for further evaluation, and selected 42 studies. Results on sex hormones, sexual function, fertility and pregnancy and offspring outcomes were reported in 13, 12, 3 and 14 SS-related articles, respectively. The levels of some sex hormones in SS patients may have undergone changes. Female patients with SS have a high prevalence of sexual dysfunction compared with controls. Most studies suggested SS had an adverse impact on maternal and fetal outcomes following pregnancy. However, there is insufficient evidence that directly indicating the fertility of SS women is diminished. CONCLUSIONS: In summary, certain aspects of sexual health (sexual function, sex hormones and pregnancy outcomes) are impaired in SS women. Screening for sexual health problems in SS female should become an integral part of medical clinical practice. Rheumatologists should be aware of this association and collaborate with gynecologists, obstetricians, psychologists, and other experts on this issue to determine appropriate therapeutic approaches.
Asunto(s)
Artritis Reumatoide , Lupus Eritematoso Sistémico , Salud Sexual , Síndrome de Sjögren , Embarazo , Humanos , Femenino , Masculino , Síndrome de Sjögren/complicaciones , Síndrome de Sjögren/diagnóstico , Artritis Reumatoide/complicaciones , Lupus Eritematoso Sistémico/complicaciones , Lupus Eritematoso Sistémico/epidemiología , Hormonas Esteroides GonadalesRESUMEN
OBJECTIVE: To learn about the prevalence and risk factors of coronary artery disease (CAD) in rheumatoid arthritis (RA). METHODS: Data were obtained from a 12-month retrospective investigation of the patients with RA, randomly selected from Departments of Rheumatology and Immunology in 21 big hospitals in China. The data were collected about their social conditions, clinical conditions, medications associated with RA, such as disease modifying anti-rheumatic drugs (DMARDs), non steroidal anti-inflammatory drugs (NSAIDs), glucocorticoid, biologic agents. A nonparameter test and multivariate logistic regression analysis were performed. RESULTS: In the study, 960 patients were enrolled. The prevalence of CAD was 3.5% in China, which was obviously higher than that of normal people. The prevalence of overweight and obesity, smoking, hypertension, diabetes mellitus, hypercholesterolemia and cerebrovascular disease were 35.1%, 12.3%, 17.0%, 7.7%, 0.4% and 3.0%, respectively. Compared with the control group, the CAD group had higher age [(64.7±9.3) years vs. (52.3±14.0) years,P<0.001], more rheumatoid nodules (14.7% vs. 3.1%,P=0.005), lower rate of hydroxychloroquine (HCQ) use (5.9% vs. 22.6%,P=0.021), higher prevalence rates of lung interstitial disease (17.5% vs. 7.0%,P<0.001), diabetes mellitus and hypertension (29.4% vs. 7.0%,P<0.001; 38.2% vs. 16.2%,P=0.001). There was no obvious correlation of CAD in RA with joint deformity, rheumatoid factor (RF) titer, glucocorticoid use, hypercholesterolemia and body mass index (BMI). Multivariate analysis showed higher age, diabetes mellitus and hypertension were independent predictors of CAD, and the use of HCQ was a protective factor of CAD. CONCLUSION: The prevalence of CAD is 3.5%. Higher age, diabetes mellitus and hypertension are independent predictors of CAD, and the use of HCQ is a protective factor of CAD.
Asunto(s)
Artritis Reumatoide/complicaciones , Enfermedad de la Arteria Coronaria/complicaciones , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Niño , China/epidemiología , Enfermedad de la Arteria Coronaria/epidemiología , Diabetes Mellitus Tipo 2/complicaciones , Femenino , Humanos , Hipertensión/complicaciones , Masculino , Persona de Mediana Edad , Prevalencia , Factores de Riesgo , Encuestas y Cuestionarios , Adulto JovenRESUMEN
OBJECTIVE: To investigate the medication status of rheumatoid arthritis (RA) patients and to analyze the clinical use of sulphasalazine (SSZ) and the adverse effect. METHODS: A total of 1 096 outpatients and inpatients diagnosed with RA were investigated in 21 hospitals all over China from July 2009 to December 2010, including gender, age of onset, clinical manifestations, as well as the clinical characteristics and medication status of 160 RA patients who received SSZ therapy. RESULTS: In the group of 160 patients who received SSZ, the male-to-female ratio was 1:7, The average age at onset was (46.1±15.0) years, while the average course was (9.9±7.8) years. The average dose of sulphasalazine was (1.87±0.52) g/d for a mean duration of (26.3± 14.6) months. Only 17% (27/160) of the patients received SSZ monotherapy. Methotrexate (63.1%), leflunomide (36.2%) and hydroxychloroquine (18.1%) were most commonly used combination drugs. And 36.2% (58/160) of the patients used the two-drug combination of methotrexate plus sulphasalazine .In this group, 41.9% (67/160) once used SSZ but withdrew for adverse events and other reasons, while 17.5% (28/160) withdrew for adverse events, of which the most common were gastrointestinal (8.8%), skin (3.8%) and liver toxicity (3.1%). CONCLUSION: Sulphaszlazine is not a common choice in the RA therapeutics in China, and the average dose of SSZ is lower than the standard dose of 2 to 3 g/d . The adverse events of SSZ are common; however, there are few severe adverse events or threat to life,SSZ is relatively safe in clinical practice.
Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Sulfasalazina/administración & dosificación , Adulto , Anciano , Antiinflamatorios no Esteroideos/efectos adversos , Antirreumáticos/uso terapéutico , China , Estudios Transversales , Quimioterapia Combinada , Femenino , Humanos , Isoxazoles/administración & dosificación , Leflunamida , Masculino , Metotrexato/administración & dosificación , Persona de Mediana Edad , Sulfasalazina/efectos adversos , Encuestas y CuestionariosRESUMEN
In an attempt to establish the advantages of fluorescence in situ hybridization (FISH) studies over conventional cytogenetic (CC) analysis, a total of 2302 de novo MDS patients from 31 Chinese institutions were prospectively selected in the present study for both CC and standardized FISH analysis for +8, -7/7q-, -5/5q-, 20q- and-Y chromosomal abnormalities. CC analysis was successful in 94.0% of the patients; of these patients, 35.9% of the cases were abnormal. FISH analysis was successful in all 2302 patients and detected at least one type of common cytogenetic abnormality in 42.7% of the cases. The incidences of +8, -7/7q-, -5/5q-, 20q- and-Y chromosomal abnormalities by FISH were 4.1% to 8.7% higher than those by CC. FISH identified abnormalities in 23.6% of the patients exhibiting normal CC results and revealed that 20.7% of the patients with adequate normal metaphases (≥20) had abnormal clones. FISH identified cytogenetic abnormalities in 50.4% of the patients with failed CC analysis. In summary, our multicenter studies emphasised and confirmed the importance of applying standardized FISH testing based on an appropriate panel of probes to detect common cytogenetic abnormalities in Chinese de novo MDS patients, particularly those with normal or failed CC results.
Asunto(s)
Análisis Citogenético/métodos , Colorantes Fluorescentes , Hibridación Fluorescente in Situ , Síndromes Mielodisplásicos/diagnóstico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , China , Aberraciones Cromosómicas , Análisis Citogenético/normas , Femenino , Humanos , Hibridación Fluorescente in Situ/métodos , Hibridación Fluorescente in Situ/normas , Masculino , Persona de Mediana Edad , Síndromes Mielodisplásicos/genética , Valor Predictivo de las Pruebas , Estudios Prospectivos , Estándares de Referencia , Adulto JovenRESUMEN
The aim of this study is to investigate the remission rate of rheumatoid arthritis (RA) in China and identify its potential determinants. A multi-center cross-sectional study was conducted from July 2009 to January 2012. Data were collected by face-to-face interviews of the rheumatology outpatients in 28 tertiary hospitals in China. The remission rates were calculated in 486 RA patients according to different definitions of remission: the Disease Activity Score in 28 joints (DAS28), the Simplified Disease Activity Index (SDAI), the Clinical Disease Activity Index (CDAI), and the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean definition. Potential determinants of RA remission were assessed by univariate and multivariate analyses. The remission rates of RA from this multi-center cohort were 8.6% (DAS28), 8.4% (SDAI), 8.2% (CDAI), and 6.8% (Boolean), respectively. Favorable factors associated with remission were: low Health Assessment Questionnaire (HAQ) score, absence of rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP), and treatment of methotrexate (MTX) and hydroxychloroquine (HCQ). Younger age was also predictive for the DAS28 and the Boolean remission. Multivariate analyses revealed a low HAQ score, the absence of anti-CCP, and the treatment with HCQ as independent determinants of remission. The clinical remission rate of RA patients was low in China. A low HAQ score, the absence of anti-CCP, and HCQ were significant independent determinants for RA remission.
Asunto(s)
Antirreumáticos/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Inducción de Remisión , Adulto , Anciano , Artritis Reumatoide/diagnóstico , China , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de Riesgo , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
This study was aimed to investigate the clinical value of detecting BCR/ABL fusion gene by fluorescence in situ hybridization (FISH). The conventional cytogenetic test and detection of BCR/ABL fusion gene by FISH for bone marrow of patients with newly diagnosed chronic myeloproliferative disease or myelodysplastic and myeloproliferative disorders, acute lymphocytic leukemia and chronic myelogenous leukemia (CML) after allogeneic hematopoietic stem cell transplantation were carried out. The results showed that (1) out of 46 newly diagnosed as chronic myeloproliferative disease or myelodysplastic and myeloproliferative disorders, 22 cases were diagnosed as CML, the FISH detection showed all positive (100%), while cytogenetic test showed 86.4% (19/22) positive, in the other 24 patients who were diagnosed as other chronic myeloproliferative disease or myelodysplastic and myeloproliferative disorders, BCR/ABL fusion gene all were be detected as negative 100% by FISH, while the cytogenetic test of bone marrow in 3 cases supported the diagnosis of CML, and the diagnosis of myelodysplastic disorder in 1 case; (2) in 3 out of 7 acute lymphocytic leukemia cases the BCR/ABL fusion gene could not be detected by FISH; (3) the BCR/ABL fusion gene could be detected by FISH in 2 cases of CML received allogeneic hematopoietic stem cell transplantation, with abnormal threshold 6.5% and 1.2% respectively. It is concluded that the detection of BCR/ABL fusion gene by FISH is sensitive and reliable, which is very important for the diagnosis and differential diagnosis of chronic myeloproliferative disorders, myelodysplastic and myeloproliferative disease, as well as definite diagnosis of Ph(+) acute lymphoblastic leukemia. This method also has an important significance for monitor of minimal residual disease in CML patients received allogeneic hematopoietic stem cell transplantation.
Asunto(s)
Proteínas de Fusión bcr-abl/genética , Hibridación Fluorescente in Situ/métodos , Leucemia/diagnóstico , Trastornos Mieloproliferativos/diagnóstico , Adolescente , Adulto , Anciano , Niño , Femenino , Genes abl , Humanos , Leucemia/genética , Masculino , Persona de Mediana Edad , Trastornos Mieloproliferativos/genética , Adulto JovenRESUMEN
OBJECTIVE: The aim of this investigation was to examine the changes of the color stability, surface microstructure and chemical constitution of light-curing composite resin after accelerated aging, and the relations between them. METHODS: Four light-curing composite resin were aged in an accelerated aging instrument. The color was measured by CIE L*a*b* with a spectrophotometer after treatment for 24 h and 96 h. And the color differences were calculated. Environmental scanning electron microscopy (ESEM) and Fourier transform infrared spectroscopy (FTIR) spectrometer were used to examine the microstructure and chemical composition of the specimens before and after accelerated aging. The color differences were analyzed statistically by repeated-measures two-way analysis of variance and t-test after aging for 24 h and 96 h. The level of significance was defined as alpha=0.05. RESULTS: The materials demonstrated statistically significant differences in color after aging between the 24 h and 96 h (P<0.05). There were significant influences on the microstructure and the chemical composition after aging. The matrix appeared some concaves and pores, the filler particles exposed after aging. The energy of chemical bonds were weaken or broken under the aging, and the unsaturated polymer reacted again. CONCLUSION: The color differences of the composite resin increase with the aging time and irradiation dose. The hybrid filled composites have the best color stability.
Asunto(s)
Luces de Curación Dental , Ensayo de Materiales , Color , Resinas Compuestas , Materiales Dentales , Humanos , EspectrofotometríaRESUMEN
This study was purpose to explore the effect of combination of SCF, FL, TPO without serum and stroma on the ex vivo expansion of the mononuclear cells derived from umbilical cord blood (CB) and to evaluate the proper infused time and implantation of expanded cells. Mononuclear cells derived from CB were cultured with the combination of SCF, FL and TPO for 14 days. At 0, 7, 10 and 14 days, the total mononuclear cells in culture were counted, CD34+ cells and CD34+CXCR4+, CD34+CD49d+ cells were assayed by flow cytometry, and CFU were determined. Mononuclear cells from CB cultured for 7 days ex vivo in serum- and stroma-free medium containing FL+SCF+TPO were infused into sublethally irradiated NOD/SCID mice. Six weeks after transplantation, the human cells were assessed by flow cytometry and PCR. The results showed that after culturing ex vivo in the presence of SCF+FL+TPO for 14 days, the total number of nuclear cells significantly increased in the early stage of culture, CD34+, CD34+CD49d+ cells reached a peak level at 7 days and then decreased, while the peak level of CFU, CD34+CXCR4+ cells was at 10 days, then decreased. Human hematopoietic cells could be detected in the marrow of the recipients at 6 weeks after infusion and the rate of success of NOD/SCID mice implanted with the expanded cells was higher than mice transplanted with fresh sample and control (p<0.05). It is concluded that day 7-10 may be an optimal harvest time for transplantation. The expanded cells with FL+SCF+TPO can be engrafted into the bone marrow of sublethally irradiated NOD/SCID mice. The engrafting potential of cord blood may be enhanced via up-regulating CXCR4 and CD49d expression on the CD34+ cells.
Asunto(s)
Proliferación Celular/efectos de los fármacos , Sangre Fetal/citología , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/trasplante , Animales , Antígenos CD34/análisis , Células Cultivadas , Humanos , Ratones , Ratones Endogámicos NOD , Ratones SCID , Factor de Células Madre/farmacología , Trombopoyetina/farmacología , Trasplante Heterólogo , Tirosina Quinasa 3 Similar a fms/farmacologíaRESUMEN
OBJECTIVE: To evaluate the matching of the shade between beverage and modifying porcelain shade guide according to Munsell color order system, thus to provide the reference basis for selecting modifying porcelain to mimic the stain of natural tooth by technician. METHODS: The shade of Vita Akzent, Vita Interno, Shofu Vintage & Unibond and Noritake Super Porcelain EX-3 shade tabs as well as 15 kinds of beverage were measured according to Munsell color order system on Color-Eye 7000A spectrophotometer. The difference of the frequency of approximate hue, value, and chroma between shade tabs and beverage were compared by calculating the Fisher exact probabilities. RESULTS: The frequency of approximate hue between 4 kinds of shade tabs and 15 kinds of bev-erage was significant different (P<0.05), while the frequency of approximate value, and chroma was not significant different (P>0.05). CONCLUSION: Except the hue, the color distribution of 4 kinds of shade tabs was similar to that of 15 kinds of beverage. But the color of beverage also can be approximately matched by any kind of modifying porcelain by mixing porcelain powder of appropriate hue, value, and chroma.
Asunto(s)
Porcelana Dental , Coloración de Prótesis , Bebidas , Color , ColorimetríaRESUMEN
To simultaneously compare and evaluate the examinations of bone marrow smear and trephine biopsy in differential diagnosis and therapeutical effect of pancytopenia patients, the differences between bone marrow smear and trephine biopsy in degree of cellularity, misdiagnosis rate and therapeutical effect for 71 patients with pancytopenia were analyzed. The results showed that the degree of cellularity in bone marrow biopsy for cytologic morphology was higher than that from the smear, but misdiagnosis rate in the biopsy was lower than that in the smear. In conclusion, bone marrow biopsy is necessary to the differential diagnosis and more valuable for evaluation of therapeutical effect and prognosis of pancytopenia patients.